Background: Ovarian cancer has been named "the silent killer" because it frequently causes non-specific symptoms which contribute to diagnostic delay. Despite of the improved surgical techniques and effective chemotherapeutic regimens available for management of ovarian cancer, there is no improvement in its early detection. Thus, ovarian cancer remains a leading cause of death from gynecological malignancies with an overall poor prognosis. The identification of novel cancer biomarker opens the possibility for early detection, and better monitoring of tumor progression. Haptoglobin is a novel biomarker which was used in diagnosis in ovarian cancer.
INTRODUCTION
Ovarian cancer is a lethal gynecologic malignancy with greater than 70% of women presenting with advanced stage disease. Despite new treatments, long term outcomes have not significantly changed in the past 30 years with the fiveyear overall survival remaining between 20% and 40% for stage III and IV disease. In contrast patients with stage I disease have a greater than 90% five-year overall survival. Detection of ovarian cancer at an early stage would likely have significant impact on mortality rate (Cohen et al., 2014).
Given our knowledge about the steep decrease in survival rates relative to the stage at which the disease is diagnosed, it is reasonable to suggest that early detection remains the most promising approach with which to improve the long-324 term survival of ovarian cancer patients. Therefore, considerable efforts have been focused on the identification of diagnostic biomarkers for early detection of ovarian cancer (Donach et al., 2010 and The present work aimed to assess the performance of haptoglobin and CA125 to increase the sensitivity and specificity in diagnosis of nature of ovarian mass.
PATIENTS AND METHODS
This study was carried out on 90 women attending at Al-Hussein, Bab El-Sha'aria University Hospital and outpatient Gynecological Clinic. After informed consents were obtained, those patients were subjected to careful history taking, clinical examination, ultrasound examination and preoperative assessment of serum levels of Haptoglobin and CA125.
Enrollment of study group in our study and their division into patients having either benign or malignant masses done according to postoperative histopathological examination , patient with krukenberg tumors and those having metastatic tumors were excluded from our study. Preoperative assessment of serum levels of Haptoglobin and CA125 was done in all cases.
A. Study Group:
Consists of 60 women with ovarian mass scheduled for surgery.
It was subdivided into two groups:
Subgroup I includes 30 cases diagnosed as having malignant ovarian tumors.
Subgroup II includes 30 cases diagnosed as having benign ovarian tumors.
B. Control group:
Consists of 30 healthy non pregnant women don't have ovarian mass.
All the removed specimens were sent for histo-pathological diagnosis using paraffin sections and stained with haemtoxylin and eosin stain.
Corroboration of the histopathology with serum haptoglobin and CA125 was done to assess the value of these preoperative investigations for discrimination between benign and malignant tumors.
Statistical analysis of the data
Data were fed to the computer using IBM SPSS software package version 20.0.
Qualitative data were described using number and percent. Comparison between different groups regarding categorical variables was tested using Chi-square test.
Quantitative data were described using mean and standard deviation for normally distributed data between two independent populations using independent t-test, while more than two populations were analyzed using F-test (ANOVA).
Correlations between two quantitative variables were assessed using Pearson coefficient.
Significance test results were quoted as two-tailed probabilities, and the obtained results were judged at the 5% level.
RESULTS
The data which were obtained from history, symptoms, clinical examination, ultrasonic assessment and tumor markers measurement, were compared with the operative findings and the final histopathological findings of the masses in order to assess the diagnostic role of Haptoglobin biomarker in ovarian cancer.
In this study, out of the 97 subjects primarily enrolled, 60 patients with ovarian mass (30 case as benign and 30 case as malignant) and 30 cases as a control, 7 cases were excluded, as they were found to have secondary ovarian tumors (5 cases of krukenberg tumors and 2 cases of endometrial clear cell tumor). On analysis of both serum CA-125 and haptoglobin, it was found that there was a significant difference between the three studied groups with p value =0.0001 (Table 1) . Analysis of CA-125 as a single biomarker using calculated cut off value >36 U/ml showed that the sensitivity of CA-125 was 90.0%, specificity 92.0%, 326 positive predictive value 88.0%, and negative predictive value 91.0% in the diagnosis of malignant ovarian tumors with p value = 0.002 ( Table 2) .
Analysis of serum haptoglobin using calculated cut off value >1.9 mg /ml showed that the sensitivity of haptoglobin was 88.0%, specificity 85.0% and positive predictive value 84.0% in the diagnosis of malignant ovarian tumors with p value = 0.0016 (Table 3) . Analysis of both serum CA-125 and haptoglobin biomarkers using calculated cut off value >36 U/ml and >1.9 mg/ml respectively showed that the sensitivity of both was 94.0%, specificity 93.0%, positive predictive value 95.0%, and negative predictive value 92.0% in the diagnosis of malignant ovarian tumors with p value = 0.001 (Table 4 ). 
DISCUSSION
In the present study, CA-125 at a cut off 36 U/ml was a significant predictor of malignancy in the studied cases. 
In agreement with Ong et al. (2013)
found that mean serum CA-125 was significantly higher in patients with cancer ovary compared to normal subjects, patients with benign tumors and patients with other gynecological cancers.
In the current study, at cut off value of 36U/ml, the predictive value of serum CA-125 in diagnosis of malignant ovarian tumors showed sensitivity (90%), specificity (92%), positive predictive value (88%), and negative predictive value (91%). In the current study, the serum CA-125 ranged from 88-463 with a mean value of 231.93 in malignant group. It was significantly lower in benign compared to malignant group. In the current study, at cut off value of 1.9 mg/ml, the accuracy value of serum haptoglobin in diagnosis of malignant ovarian tumors showed sensitivity was 88%, specificity (85%), positive predictive value (84%) and negative predictive value (83%).
In the current study, the serum haptoglobin ranged from 0.5-10.5 mg/ml with a mean of 5.94 in malignant group. It was significantly different from control group.
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The serum haptoglobin in benign group ranged from 1-1.8 mg/ml with a mean 1.50 which was significantly different from than control group. It was found that serum level of haptoglobin in malignant and benign group was significantly different from control group, while serum level of haptoglobin in malignant cases were more than that in the benign cases.
These results were in agreement with Kim et al. (2009) who found that haptoglobin in malignant cases were significant difference from normal controls, benign ovarian tumors and other gynecological cancers respectively, and agreed with Zhao et al. (2007) who found that haptoglobin concentration were significantly higher in late stage ovarian cancer than benign and healthy controls, and there was a significant difference between early stage cancer and healthy controls.
This was in agreement with Weiz et al. (2016) who found that, in the group of ovarian cancer, haptoglobin level was more than three times than control groups. In the group of nonmalignant tumors, the haptoglobin level was twice as high as in the control group.
The combined ability of both markers (serum CA-125 and serum haptoglobin) to detect ovarian malignant tumors was tested in the current study at the cut off value of 36 U/ml for serum CA-125 and 1.9 mg/ml for serum haptoglobin. The predictive values of both markers together in diagnosis of malignant ovarian tumor showed sensitivity (94%), specificity (93%), positive predictive value (95%) and negative predictive value (92%).
The results of the present study were similar to that of Kim et al. (2009) who found that the combined ability of both markers (serum CA-125 and serum haptoglobin) showed better results with 91% sensitivity and 95% specificity in the whole study groups.
CONCLUSION
Haptoglobin has an important role in the prediction of ovarian cancer and its serum level increased in early stages of cancer ovary. It increased significantly in malignant ovarian tumors than in benign ovarian tumors. So, it can be used as a diagnostic tumor marker in cases of ovarian neoplasia. So, haptoglobin was a novel marker for ovarian cancer with accuracy near to that of CA-125. The combination of haptoglobin and CA-125 showed better prediction than haptoglobin or CA-125 alone.
